ADMS Adamas Pharmaceuticals Inc.

Adamas to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020

Adamas to Announce Third Quarter 2020 Financial Results and Host Conference Call on November 5, 2020

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 third quarter financial results on Thursday, November 5, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Investor Conference Call and Webcast

The conference call can be accessed by dialing (844) 215-3280 for participants in the U.S. or Canada and (484) 747-6383 for international callers. All callers must provide the following Conference ID: 1578986. The webcast can be accessed live via the investor section of the Adamas website at and will be available for replay until December 5, 2020.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit .

Contact

Media:

Sarah Mathieson

Vice President, Corporate Communications

510-450-3528





Investors:

Peter Vozzo

Managing Director, Westwicke

443-213-0505





EN
26/10/2020

Underlying

ADMSAdamas Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Adamas Pharmaceuticals Inc.

 PRESS RELEASE
Free
ADMS Adamas Pharmace...

Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Re...

Adamas Provides Preliminary Fourth Quarter and Full Year 2020 Total Revenues and Key Business Drivers for 2021 -- Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 -- -- Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020 and $71.2 million for full year 2020 -- -- Total prescriptions of GOCOVRI of approximately 8,165 for fourth quarter 2020 and approximately 31,070* for full year 2020 -- EMERYVILLE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated...

January 13, 2021 1 EN
 PRESS RELEASE
Free
ADMS Adamas Pharmace...

Adamas to Present at Upcoming ICR Conference

Adamas to Present at Upcoming ICR Conference EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the ICR Conference 2021, being held January 11-14, 2021. The fireside chat will be webcast live on January 14, 2021 at 11:30 a.m. Eastern Time on the investor relations section of the Adamas website at . Th...

January 7, 2021 1 EN
 PRESS RELEASE
Free
ADMS Adamas Pharmace...

Adamas Completes Acquisition of OSMOLEX ER®

Adamas Completes Acquisition of OSMOLEX ER® Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition EMERYVILLE, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the closing of the settlement of patent litigation with Osmotica Pharmaceutical US LLC, a subsidiary of Osmotica Pharmaceuticals plc and completes the acquisition of the global rights to OSMOLEX ER®. As previously disc...

January 5, 2021 1 EN
 PRESS RELEASE
Free
ADMS Adamas Pharmace...

Adamas to Present at Upcoming H.C. Wainwright Conference

Adamas to Present at Upcoming H.C. Wainwright Conference EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright VIRTUAL BioConnect Conference, being held January 11 – 14, 2021. A replay of the pre-recorded fireside chat will be available beginning January 11, 2021 in the in...

January 4, 2021 1 EN
 PRESS RELEASE
Free
ADMS Adamas Pharmace...

Adamas Announces New Employment Inducement Grant

Adamas Announces New Employment Inducement Grant EMERYVILLE, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 28,500 shares of the company’s common stock, at a per share exercise price of $4.88, the closing trading price on December 7, and restricted stock units to acquire 14,250 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuan...

December 11, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch